GlassScriptPhysician profile
Lesley Macinnes
NPI 1235577602
$689.99
in general payments reported to CMS, 2019-2025
15 companies · $210 in 2025
The $210 reported for 2025 was more than what 75% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2021: $45.25 · 2023: $51.37 · 2024: $228 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $489.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $255.32 | 2021-2024 | Qelbree, Qelbree |
| Neos Therapeutics, LP | $75.76 | 2019 | |
| Pfizer INC. | $59.86 | 2024-2025 | |
| Collegium Pharmaceutical, INC. | $52.23 | 2025 | Jornay Pm |
| Acadia Pharmaceuticals INC | $40.93 | 2025 | Daybue |
| Sanofi-Aventis U.S. LLC | $35.76 | 2024-2025 | |
| Ironshore Pharmaceuticals INC. | $27.94 | 2019 | |
| Novo Nordisk INC | $22.14 | 2025 | |
| Glaxosmithkline, LLC. | $19.00 | 2019 | |
| Seqirus USA INC | $18.89 | 2024 | Flucelvax |
| Tris Pharma INC | $18.07 | 2025 | Dyanavel Xr |
| Sobi, INC | $16.69 | 2023 | |
| Rhodes Pharmaceuticals L.P. | $16.68 | 2019 | |
| Shire North American Group INC | $15.77 | 2019 | |
| Merck Sharp & Dohme LLC | $14.95 | 2025 | Gardasil 9, Enflonsia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lesley Macinnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.